SAVA vs. COLL, VRCA, NATR, SCPH, VSTM, ALKS, PRGO, CRNX, AXSM, and BHVN
Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Collegium Pharmaceutical (COLL), Verrica Pharmaceuticals (VRCA), Nature's Sunshine Products (NATR), scPharmaceuticals (SCPH), Verastem (VSTM), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), Axsome Therapeutics (AXSM), and Biohaven (BHVN). These companies are all part of the "pharmaceutical preparations" industry.
Cassava Sciences (NASDAQ:SAVA) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
Cassava Sciences has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
Collegium Pharmaceutical has a net margin of 16.46% compared to Cassava Sciences' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.98% beat Cassava Sciences' return on equity.
Collegium Pharmaceutical received 281 more outperform votes than Cassava Sciences when rated by MarketBeat users. However, 66.43% of users gave Cassava Sciences an outperform vote while only 65.16% of users gave Collegium Pharmaceutical an outperform vote.
Cassava Sciences currently has a consensus price target of $131.00, indicating a potential upside of 494.64%. Collegium Pharmaceutical has a consensus price target of $39.00, indicating a potential upside of 17.68%. Given Cassava Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cassava Sciences is more favorable than Collegium Pharmaceutical.
Collegium Pharmaceutical has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Collegium Pharmaceutical had 9 more articles in the media than Cassava Sciences. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 2 mentions for Cassava Sciences. Collegium Pharmaceutical's average media sentiment score of 0.60 beat Cassava Sciences' score of 0.36 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.
38.1% of Cassava Sciences shares are owned by institutional investors. 9.0% of Cassava Sciences shares are owned by insiders. Comparatively, 4.0% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Collegium Pharmaceutical beats Cassava Sciences on 11 of the 16 factors compared between the two stocks.
Get Cassava Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cassava Sciences Competitors List
Related Companies and Tools
